9. Dynavax Technologies (DVAX), is a biopharmaceutical company that discovers and develops products to prevent and treat infectious diseases, asthma, and other inflammatory and autoimmune disorders. Its main product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine.
Of the five analysts covering the stock, 80% recommend a buy. The stock's average 12-month price target is $5.00, about 98.4% higher than the current price, according to a Bloomberg consensus.
Cash, cash equivalents and marketable securities for the first quarter of 2011 stood at $53.2 million. At close of the quarter, DVAX earned a $6 million milestone payment from GlaxoSmithKline for the initiation of a Phase-1 trial in the partnered lupus program. The company reported multifold increase in service and license revenue to $489,000 from $61,000 in the year-ago quarter. Moreover, R&D expenses increased to $14.7 million from $12.5 million.In the third week of May 2011, the company reported the completion of the 12-month follow-up on all the 2,449 subjects enrolled in its large-scale Phase III study of HEPLISAV evaluating immunogenicity in comparison to Engerix, lot-to-lot consistency and safety. With the study completed, Dynavax expects to report results within eight weeks. The company anticipates ongoing quarterly spend to decline through the remainder of 2011 such that its average quarterly net cash usage approximates $13 million for 2011.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV